Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 18/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.57 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14198754 | 1.00 | HDAC8 (0.57) | HDAC8HDAC1HDAC3HDAC2HDAC6 | |
| SCHEMBL25578544 | 0.85 | HDAC8 (0.48) | HDAC8HDAC1HDAC3HDAC2HDAC6 | |
| SCHEMBL44905 | 0.85 | HDAC8 (0.58) | HDAC8HDAC1HDAC3HDAC2HDAC6 | |
| SCHEMBL1613174 | 0.85 | HDAC8 (0.58) | HDAC8HDAC1HDAC3HDAC2HDAC6 | |
| SCHEMBL12958085 | 0.85 | HDAC8 (0.58) | HDAC8HDAC1HDAC3HDAC2HDAC6 | |
| SCHEMBL44904 | 0.85 | HDAC8 (0.58) | HDAC8HDAC1HDAC3HDAC2HDAC6 | |
| SCHEMBL29350881 | 0.85 | HDAC8 (0.58) | HDAC8HDAC1HDAC3HDAC2HDAC6 | |
| SCHEMBL29868418 | 0.85 | HDAC8 (0.58) | HDAC8HDAC1HDAC3HDAC2HDAC6 | |
| SCHEMBL12391476 | 0.84 | HDAC8 (0.54) | HDAC8HDAC1HDAC3HDAC2HDAC6 | |
| SCHEMBL12194017 | 0.83 | HDAC8 (0.53) | HDAC8HDAC1HDAC3HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160152576-A9 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2016-06-02 | — | — | US | disclosed |
| US-20140148436-A1 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2014-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148436-A1 | AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT3 | HDAC8 1441/4885HDAC1 738/4885HDAC3 1587/4885 |
| US-20160152576-A9 | AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT3 | HDAC8 1441/4885HDAC1 738/4885HDAC3 1587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.